IDX 9059
Alternative Names: DIMS-9059; IDX 9059Latest Information Update: 28 Nov 2024
At a glance
- Originator InDex Pharmaceuticals
- Developer Flerie
- Class Anti-inflammatories; Oligonucleotides
- Mechanism of Action Toll-like receptor 9 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 28 Nov 2024 No recent reports of development identified for preclinical development in Inflammation in Sweden (Parenteral)
- 25 Nov 2022 IDX 9050 is still in preclinical development for Inflammation in Sweden (Index Pharmaceuticals pipeline, November 2022)
- 28 Apr 2022 No recent reports of development identified for preclinical development in Inflammation in Sweden (Parenteral)